放疗、全身治疗及治疗顺序对黑色素瘤脑转移患者生存的影响
该回顾性分析纳入208例在放疗前后6周内接受免疫治疗或靶向治疗的黑色素瘤脑转移患者,评估总生存。立体定向放疗联合免疫治疗的一年生存率最高(69%),BRAF突变者接受免疫联合放疗的一年生存率达88%。靶向治疗在放疗后或跨放疗使用较仅放疗前使用改善中位总生存。
要点
- 立体定向放疗联合免疫治疗的一年生存率为69%,高于其他组合。
- BRAF突变患者接受免疫联合放疗的一年生存率可达88%。
- 靶向治疗在放疗后或跨放疗使用较仅放疗前使用改善中位总生存。
核心结论
- 立体定向放疗联合免疫治疗获得最高总生存率,BRAF突变似乎是总生存的有利预后因素,放疗与靶向治疗联合时顺序似乎至关重要。
- 全脑放疗联合全身治疗获得前所未有的高总生存率,值得进一步研究。
研究设计与样本
- 回顾性分析208例接受立体定向放疗或全脑放疗且在放疗前后6周内接受免疫治疗或靶向治疗的黑色素瘤脑转移患者。
- 总生存从放疗起算至死亡或末次随访,采用单因素和多因素Cox比例风险分析确定与总生存相关的预后特征。
主要发现
- 中位随访7.3个月,139例接受免疫治疗,67例接受靶向治疗,2例接受免疫联合靶向治疗(全脑放疗45%,立体定向放疗55%)。
- 立体定向放疗联合免疫治疗、立体定向放疗联合靶向治疗、全脑放疗联合免疫治疗、全脑放疗联合靶向治疗的一年Kaplan-Meier总生存率分别为69%、65%、33%和18%(P < .001)。
- BRAF突变患者接受免疫联合放疗的总生存率分别为88%、65%、50%和18%。
- 靶向治疗在放疗后或放疗前开始并持续至放疗后,较仅放疗前使用靶向治疗改善中位总生存:12.2个月(95%CI 9.3-15.1)和9.8个月(95%CI 6.9-12.6)对比5.1个月(95%CI 2.7-7.5),P = .03。
临床怎么用
- 作者认为立体定向放疗联合免疫治疗获得最高总生存率,BRAF突变似乎是总生存的有利预后因素。
- 作者认为放疗与靶向治疗联合时顺序似乎至关重要,全脑放疗联合全身治疗获得的高总生存率值得进一步研究。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Combining stereotactic radiosurgery (SRS) and active systemic therapies (STs) achieved favourable survival outcomes in patients with melanoma brain metastases (MBMs) in retrospective analyses. However, several aspects of this treatment strategy remain poorly understood. We report on the overall survival (OS) of patients with MBM treated with a combination of radiotherapy (RT) and ST as well as the impact of the v-Raf murine sarcoma viral oncogene homolog B (BRAF)-V600 mutation (BRAFmut) status, types of RT and ST and their sequence. PATIENTS AND METHODS: Data of 208 patients treated with SRS or whole brain radiation therapy (WBRT) and either immunotherapy (IT) or targeted therapy (TT) within a 6-week interval to RT were analysed retrospectively. OS was calculated from RT to death or last follow-up. Univariate and multivariate Cox proportional hazard analyses were performed to determine prognostic features associated with OS. RESULTS: The median follow-up was 7.3 months. 139 patients received IT, 67 received TT and 2 received IT and TT within 6 weeks to RT (WBRT 45%; SRS 55%). One-year Kaplan-Meier OS rates were 69%, 65%, 33% and 18% (P < .001) for SRS with IT, SRS with TT, WBRT with IT and WBRT with TT, respectively. Patients with a BRAFmut receiving IT combined with RT experienced higher OS rates (88%, 65%, 50% and 18%). TT following RT or started before and continued thereafter was associated with improved median OS compared with TT solely before RT (12.2 [95% confidence interval {CI} 9.3-15.1]; 9.8 [95% CI 6.9-12.6] versus 5.1 [95% CI 2.7-7.5]; P = .03). CONCLUSION: SRS and IT achieved the highest OS rates. A BRAFmut appears to be a favourable prognostic factor for OS. For the combination of RT and TT, the sequence appears to be crucial. Combinations of WBRT and ST achieved unprecedentedly high OS rates and warrant further studies.
引用
- Rauschenberg R, Bruns J, Brütting J, et al. Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases. Eur J Cancer. 2019. PMID: 30739835. doi:10.1016/j.ejca.2018.12.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。